Revolution Medicines, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Revolution Medicines, Inc. (RVMD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $67.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $67.00M, a 132.40% increase year-over-year.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $87.30M, a 248.03% increase year-over-year.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $30.78M, a 48.15% increase year-over-year.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $28.83M, a 45.79% increase year-over-year.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $118.39M, a 49.49% increase from fiscal 2024.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $79.20M, a 28.21% increase from fiscal 2023.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $61.77M, a 98.01% increase from fiscal 2022.
- Revolution Medicines, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $31.20M, a 50.53% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.00M 10-Q · filed 2026-08-05 | $154.30M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $87.30M 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $118.39M 10-K · filed 2026-02-25 | |||
| 2025-09-30 | $30.78M 10-Q · filed 2025-11-05 | $59.61M derived: sum of 2 quarters · filed 2026-08-05 | $84.69M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-30 | $28.83M 10-Q · filed 2026-08-05 | $53.91M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-31 | $25.08M 10-Q · filed 2026-08-05 | |||
| 2024-12-31 | $79.20M 10-K · filed 2026-02-25 | |||
| 2024-09-30 | $20.77M 10-Q · filed 2025-11-05 | $40.55M derived: sum of 2 quarters · filed 2025-11-05 | $56.76M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $19.77M 10-Q · filed 2025-11-05 | $35.98M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $16.21M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $61.77M 10-K · filed 2026-02-25 | |||
| 2023-09-30 | $13.67M 10-Q · filed 2024-11-06 | $26.65M derived: sum of 2 quarters · filed 2024-11-06 | $36.34M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $12.98M 10-Q · filed 2024-11-06 | $22.68M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $9.70M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $31.20M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $8.14M 10-Q · filed 2023-11-06 | $16.24M derived: sum of 2 quarters · filed 2023-11-06 | $22.88M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $8.10M 10-Q · filed 2023-11-06 | $14.74M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $6.64M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $20.72M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | $5.83M 10-Q · filed 2022-11-07 | $11.14M derived: sum of 2 quarters · filed 2022-11-07 | $14.53M derived: sum of 3 quarters · filed 2022-11-07 | |
| 2021-06-30 | $5.31M 10-Q · filed 2022-11-07 | $8.70M derived: sum of 2 quarters · filed 2022-11-07 | ||
| 2021-03-31 | $3.39M 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $8.89M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | $2.67M 10-Q · filed 2021-11-10 | $4.69M derived: sum of 2 quarters · filed 2021-11-10 | $6.25M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $2.02M 10-Q · filed 2021-11-10 | $3.58M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $1.57M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $3.16M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $854.00K 10-Q · filed 2020-11-12 | $1.36M derived: sum of 2 quarters · filed 2020-11-12 | $1.76M derived: sum of 3 quarters · filed 2020-11-12 | |
| 2019-06-30 | $506.00K 10-Q · filed 2020-11-12 | $909.00K derived: sum of 2 quarters · filed 2020-11-12 | ||
| 2019-03-31 | $403.00K 10-Q · filed 2020-11-12 | |||
| 2018-12-31 | $855.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |